About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The main characteristic of our group is its multidisciplinary nature, as it is comprised of neuroradiologists, technologists, and a physicist, engineer, and biochemist.
The main objectives of our projects are to gain knowledge about the pathophysiologic mechanisms implicated in several neurological diseases and to evaluate new biomarkers and therapies through the use of qualitative and quantitative magnetic resonance (MR) and computed tomography (CT) techniques, and by applying artificial intelligence tools to create prognostic models. Our focus is on the study of diseases such as multiple sclerosis, epilepsy, neuro-oncology, and stroke.
In addition, because of the experience we have acquired along the years in performing MR studies, we act as a platform for designing MR-based projects, processing images, and conducting quantitative data analysis.
This line is focused on the application of computer vision, image processing, pattern recognition, machine learning and fuzzy logic techniques to the analysis of MR images. Some areas of interest are the study of lesions, and iron quantification by means of advanced techniques such as QSM and SWI.
IP: Fco. Javier Aymerich Martínez, Juli Alonso Farre
This research line is mainly focused on the assessment of intracranial aneurysms. This includes the role of several imaging techniques to predict the risk of future rupture. Other interests are to associate imaging changes with the pathophysiological mechanisms that underlie aneurysm formation and to optimize the imaging protocol used in clinical practice.
IP: Alex Rovira Cañellas
The aim of the line is to evaluate synthetic MR images compared to conventional images to consider its use in healthcare protocols.
IP: Fco. Javier Aymerich Martínez, Juli Alonso Farre, Alex Rovira Cañellas
PMID: 37702845 Journal: MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE Year: 2023 Reference: MAGMA. 2023 Sep 13. doi: 10.1007/s10334-023-01113-y. Impact factor: Publication type: Review in international publication Authors: Clement, Olivier; Dekkers, Ilona A; Gianolio, Eliana; Karst, Uwe; Mallio, Carlo Augusto; Nederveen, Aart J; Parillo, Marco; Quattrocchi, Carlo Cosimo; Radbruch, Alexander; Rovira, Alex et al. DOI: 10.1007/s10334-023-01113-y
PMID: 37705507 Journal: ANNALS OF NEUROLOGY Year: 2023 Reference: Ann Neurol. 2023 Sep 14. doi: 10.1002/ana.26793. Impact factor: Publication type: Paper in international publication Authors: Arrambide, Georgina; Auger, Cristina; Auger, Cristina; Bollo, Luca; Carbonell-Mirabent, Pere; Castillo, Joaquin; Castillo, Mireia; Cobo-Calvo, Alvaro; Cobo-Calvo, Alvaro; Comabella, Manuel et al. DOI: 10.1002/ana.26793
PMID: 37729730 Journal: BIOMEDICINE & PHARMACOTHERAPY Year: 2023 Reference: Biomed Pharmacother. 2023 Sep 18;167:115469. doi: 10.1016/j.biopha.2023.115469. Impact factor: Publication type: Paper in international publication Authors: Alonso, Judith; Alonso, Judith; Ballester-Servera, Carme; Canes, Laia; Fernandez-Celis, Amaya; Lopez-Andres, Natalia; Martinez-Gonzalez, Jose; Puertas-Umbert, Lidia; Rodriguez, Cristina; Rodriguez-Sinovas, Antonio et al. DOI: 10.1016/j.biopha.2023.115469
PMID: 37754568 Journal: EUROPEAN JOURNAL OF NEUROLOGY Year: 2023 Reference: Eur J Neurol. 2023 Sep 27. doi: 10.1111/ene.16077. Impact factor: Publication type: Paper in international publication Authors: Castillo, Joaquin; Comabella, Manuel; Comabella, Manuel; Fissolo, Nicolas; Midaglia, Luciana; Miro, Berta; Montalban, Xavier; Rio, Jordi; Rio, Jordi; Rovira, Alex et al. DOI: 10.1111/ene.16077
Els doctors Xavier Montalban, Àlex Rovira i Mar Tintoré han estat reconeguts en la categoria de Neurociències i Comportament, i el doctor Jordi Rello en la categoria Interdisciplinària.
The program, promoted by Biocat in collaboration with CIMIT (Boston), is aimed at entrepreneurs in the process of bringing their technology to market in the next few years.
